Key result
Smaller acute eGFR fall after starting MR antagonists is linked to steeper long-term eGFR decline.
Why the study?
Primary aldosteronism-specific treatment leads to an acute fall in eGFR, but its impact on long-term renal function decline was unclear.
Does the magnitude of acute eGFR fall after treatment for primary aldosteronism predict long-term eGFR decline in patients with primary aldosteronism?
Cohort (n=505)
Yes
Does the magnitude of acute eGFR fall after treatment for primary aldosteronism predict long-term eGFR decline in patients with primary aldosteronism?
A larger acute fall in eGFR following initiation of MR antagonists for primary aldosteronism is associated with a slower rate of long-term eGFR decline, suggesting it is a favorable prognostic sign.
Smaller acute eGFR fall after MR antagonists signals steeper long-term decline; leaves open whether this guides monitoring or treatment choice in primary aldosteronism.
Primary aldosteronism causes renal structural damage after glomerular hyperfiltration, and primary aldosteronism-specific treatment leads to an acute fall in estimated glomerular filtration rate (eGFR). We investigated whether this change affected the long-term eGFR slope in a retrospective cohort from the multicenter Japan Primary Aldosteronism Study. We allocated patients with primary aldosteronism to the adrenalectomy (n=202) and MR (mineralocorticoid receptor) antagonist (n=303) groups based on their treatment history and analyzed the association between the initial eGFR fall and long-term eGFR slope. The increased age, low serum potassium levels, high eGFR, and high plasma aldosterone levels were independent predictors for a large initial eGFR fall in both groups. Our analysis of tertiles based on the initial eGFR fall revealed that in the MR antagonist group, patients with a small initial eGFR fall had a significantly steeper long-term eGFR slope than those with a large initial fall (tertile 1 versus 2, P=0.025; tertile 1 versus 3, P=0.017). These associations were not identified in the adrenalectomy group. Thus, the smaller the acute fall in eGFR by initiation of MR antagonists, the greater was the rate of long-term eGFR decline. While the acute fall in eGFR induced by primary aldosteronism-specific treatment is occasionally a clinical concern, our findings highlight the favorable implications of the acute fall with respect to long-term renal outcomes.
No takes yet. Share an insight, caveat, or question.
Kobayashi et al. (2019) conducted a cohort in Primary aldosteronism (n=505). Initial eGFR fall after treatment vs. Large initial eGFR fall (tertiles) was evaluated on Long-term eGFR slope (p=0.025 (tertile 1 vs 2); 0.017 (tertile 1 vs 3)). A smaller acute fall in eGFR following initiation of MR antagonists for primary aldosteronism was associated with a significantly steeper long-term eGFR decline (tertile 1 vs 2, P=0.025).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: